Sarepta Therapeutics, Inc. (SRPT) - Q2 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2025. Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on rare diseases, primarily Duchenne muscular dystrophy (DMD) and Limb-girdle muscular dystrophies (LGMD). The company's portfolio includes PMO products (EXONDYS 51, VYONDYS 53, AMONDYS 45) and the gene therapy ELEVIDYS. The reporting period was significantly impacted by safety events related to ELEVIDYS and a major strategic restructuring announced in July 2025.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Total Revenues | $611.1 million | $362.9 million | $1,355.9 million | $776.4 million |
| Net Income (Loss) | $196.9 million | $6.5 million | $(250.6) million | $42.6 million |
| Operating Income (Loss) | $115.6 million | $(0.7) million | $(184.8) million | $34.2 million |
| Diluted EPS | $1.89 | $0.07 | $(2.57) | $0.44 |
| Cash & Investments | $850.3 million (as of June 30, 2025) | |||
| Long-term Debt | $1,139.5 million (as of June 30, 2025) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 68% in Q2 2025 and 75% YTD 2025. This was driven by a 132% increase in ELEVIDYS product revenue ($281.9M in Q2) and a significant 3,100% increase in collaboration revenue ($98.0M in Q2) due to a $63.5M milestone from Roche for ELEVIDYS approval in Japan and the expiration of a Roche option.
- Profitability Volatility: While Q2 2025 showed a net profit of $196.9M (driven by a $36.5M gain on strategic investments and a tax benefit), the YTD 2025 period resulted in a net loss of $250.6M. This YTD loss was primarily caused by a $583.8M non-cash expense for acquired in-process research and development (IPR&D) related to the Arrowhead Pharmaceuticals collaboration.
- Cost Structure: Cost of sales increased 242% in Q2 2025 due to higher inventory costs for ELEVIDYS and products sold to Roche. R&D expenses increased 14% in Q2 but surged 157% YTD due to the Arrowhead IPR&D charge.
- Cash Position: Cash and cash equivalents decreased from $1.10 billion at year-end 2024 to $510.6 million at June 30, 2025, largely due to the $825M total commitment to Arrowhead (upfront payment and equity investment).
Guidance, Outlook, Risks, and Unusual Items
- ELEVIDYS Suspension: In response to two reported cases of acute liver failure (ALF) resulting in death in non-ambulatory patients, the company suspended shipments of ELEVIDYS to non-ambulatory patients in June 2025. In July 2025, the company voluntarily suspended all U.S. shipments (including ambulatory patients) pending FDA labeling updates. Shipments to ambulatory patients resumed in late July 2025, but the suspension for non-ambulatory patients remains.
- Strategic Restructuring: In July 2025, the company announced a restructuring plan involving a 36% workforce reduction and a reprioritization of the pipeline. This is expected to result in a one-time charge of $32.0M to $37.0M in Q3 2025.
- LGMD Clinical Hold: The FDA placed a clinical hold on the company's LGMD gene therapy trials (including SRP-9003, SRP-9004, SRP-6004, and SRP-9005) in July 2025 following a patient death in the SRP-9004 trial. The company has suspended development of most LGMD programs except SRP-9003.
- Arrowhead Collaboration: The company entered a major collaboration with Arrowhead Pharmaceuticals, paying $500M upfront and investing $325M in equity. A $100M milestone payment to Arrowhead was triggered in July 2025.
- Liquidity: Management believes current cash and investments ($850.3M) are sufficient to fund operations for at least the next 12 months, despite the restructuring and suspension impacts.
Key Facts for Investor Verification
- Regulatory Status of ELEVIDYS: Verify the timeline for the FDA's final decision on the labeling supplement and the potential for a boxed warning for acute liver injury/failure, as this directly impacts the addressable market for the company's primary growth driver.
- Restructuring Execution: Monitor the Q3 2025 financials for the actual restructuring charge ($32M-$37M range) and the subsequent impact on operating expenses and headcount.
- LGMD Pipeline Viability: Assess the likelihood of the FDA lifting the clinical hold on SRP-9003, the company's most advanced LGMD candidate, given the recent safety signal in the SRP-9004 trial.
- Arrowhead Milestone Obligations: Track the $100M milestone payment made in July 2025 and the potential for the remaining $200M in near-term milestones tied to the ARO-DM1 program.
- Inventory Valuation: Review the company's inventory levels ($1.19B total) and potential for write-offs, particularly for ELEVIDYS, given the suspension of shipments to non-ambulatory patients and the risk of obsolescence.